BiomX Inc. (NYSEMKT:PHGE) Stake Cut by Johnson & Johnson

Johnson & Johnson trimmed its holdings in shares of BiomX Inc. (NYSEMKT:PHGE) by 90.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 192,321 shares of the company’s stock after selling 1,730,880 shares during the period. BiomX accounts for 0.0% of Johnson & Johnson’s portfolio, making the stock its 18th biggest position. Johnson & Johnson owned approximately 1.07% of BiomX worth $196,000 as of its most recent SEC filing.

Separately, Ikarian Capital LLC acquired a new position in shares of BiomX during the first quarter worth approximately $4,868,000. 40.57% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of BiomX in a research note on Friday, August 16th.

BiomX Trading Down 0.9 %

NYSEMKT:PHGE traded down $0.00 during trading hours on Wednesday, hitting $0.55. 53,627 shares of the company traded hands, compared to its average volume of 68,601. The company has a market capitalization of $9.98 million, a PE ratio of -0.17 and a beta of 1.31. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The stock’s fifty day moving average price is $0.85 and its 200-day moving average price is $1.99.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.